Associations of Genetic Variants at Nongenic Susceptibility Loci with Breast Cancer Risk and Heterogeneity by Tumor Subtype in Southern Han Chinese Women
Table 4
Association between four nongenic polymorphisms and ER− & PR− & HER2+ breast cancer risk.
SNP or model
Genotype or allele
Controls (%) ()
Cases (%) ()
Raw OR (95% CI)
Raw
Adjusted OR (95% CI)
Adjusted
rs13387042
Codominant model
G/G
704 (82.5%)
86 (73.5%)
Reference
Reference
G/A
145 (17%)
31 (26.5%)
1.75 (1.12–2.74)
0.01
1.68 (1.07–2.65)
0.03
A/A
4 (0.5%)
0 (0%)
0.00 (0.00–NA)
0.99
0.00 (0.00–NA)
0.99
Dominant model
G/A + A/A
149 (17.5%)
31 (26.5%)
1.70 (1.09–2.66)
0.02
1.64 (1.04–2.58)
0.04
Recessive model
G/G + G/A
849 (99.5%)
117 (100%)
Reference
Reference
A/A
4 (0.5%)
0 (0%)
0.00 (0.00–NA)
0.31
0.00 (0.00–NA)
0.31
Overdominant model
G/G + A/A
708 (83.0%)
86 (73.5%)
Reference
Reference
G/A
145 (17.0%)
31 (26.5%)
1.76 (1.12–2.75)
0.02
1.69 (1.07–2.67)
0.03
Log-additive model
G
1553 (91.0%)
203 (86.8%)
Reference
Reference
A
153 (9.0%)
31 (13.2%)
1.60 (1.04–2.46)
0.04
1.55 (1.00–2.40)
0.048
rs981782
Codominant model
T/T
360 (41.0%)
43 (36.8%)
Reference
Reference
G/T
392 (44.6%)
55 (47.0%)
1.17 (0.77–1.79)
0.46
1.22 (0.79–1.87)
0.37
G/G
127 (14.4%)
19 (16.2%)
1.25 (0.70–2.23)
0.44
1.28 (0.71–2.30)
0.41
Dominant model
G/T + G/G
519 (59.0%)
74 (63.2%)
1.19 (0.80–1.78)
0.38
1.23 (0.82–1.85)
0.31
Recessive model
T/T + G/T
752 (85.5%)
98 (83.8%)
Reference
Reference
G/G
127 (14.4%)
19 (16.2%)
1.15 (0.68–1.94)
0.61
1.15 (0.67–1.96)
0.61
Overdominant model
T/T + G/G
487 (55.4%)
62 (53.0%)
Reference
Reference
G/T
392 (44.6%)
55 (47.0%)
1.10 (0.75–1.62)
0.62
1.14 (0.77–1.68)
0.52
Log-additive model
T
1112 (63.3%)
141 (60.3%)
Reference
Reference
G
646 (36.7%)
93 (39.7%)
1.13 (0.86–1.49)
0.38
1.15 (0.87–1.51)
0.33
rs4415084
Codominant model
T/T
244 (28.4%)
41 (35%)
Reference
Reference
C/T
453 (52.8%)
54 (46.1%)
0.71 (0.46–1.10)
0.12
0.70 (0.45–1.08)
0.11
C/C
161 (18.8%)
22 (18.8%)
0.81 (0.47–1.42)
0.47
0.74 (0.42–1.30)
0.29
Dominant model
C/T + C/C
614 (71.6%)
76 (65%)
0.74 (0.49–1.11)
0.15
0.71 (0.47–1.07)
0.11
Recessive model
T/T + C/T
697 (81.2%)
95 (81.2%)
Reference
Reference
C/C
161 (18.8%)
22 (18.8%)
1.00 (0.61–1.64)
0.99
0.92 (0.56–1.52)
0.75
Overdominant model
T/T + C/C
405 (47.2%)
63 (53.9%)
Reference
Reference
C/T
453 (52.8%)
54 (46.1%)
0.77 (0.52–1.13)
0.18
0.78 (0.53–1.16)
0.22
Log-additive model
T
941 (54.8%)
136 (58.1%)
Reference
Reference
C
775 (45.2%)
98 (41.9%)
0.87 (0.65–1.15)
0.33
0.83 (0.62–1.11)
0.21
rs1562430
Codominant model
A/A
594 (67.6%)
80 (68.4%)
Reference
Reference
G/A
254 (28.9%)
31 (26.5%)
0.91 (0.58–1.41)
0.66
0.94 (0.60–1.47)
0.79
G/G
31 (3.5%)
6 (5.1%)
1.44 (0.58–3.55)
0.43
1.19 (0.47–3.00)
0.71
Dominant model
G/A + G/G
285 (32.4%)
37 (31.6%)
0.96 (0.64–1.46)
0.86
0.97 (0.64–1.48)
0.90
Recessive model
A/A + G/A
848 (96.5%)
111 (94.9%)
Reference
Reference
G/G
31 (3.5%)
6 (5.1%)
1.48 (0.60–3.62)
0.41
1.21 (0.48–3.03)
0.69
Overdominant model
A/A + G/G
625 (71.1%)
86 (73.5%)
Reference
Reference
G/A
254 (28.9%)
31 (26.5%)
0.89 (0.57–1.37)
0.59
0.93 (0.60–1.45)
0.75
Log-additive model
A
1442 (82.0%)
191 (81.6%)
Reference
Reference
G
316 (18.0%)
43 (18.4%)
1.03 (0.73–1.45)
0.88
1.01 (0.71–1.42)
0.97
Adjusted for age, age at first full-term pregnancy, menopausal status, and hormonal therapy status. OR, odds ratio; CI, confidence interval.
